Last reviewed · How we verify
Paveril — Competitive Intelligence Brief
unknown
dioxyline
Methionine aminopeptidase 1, Methionine aminopeptidase 2
Oncology
Live · refreshed every 30 min
Target snapshot
Paveril (dioxyline). Paveril works by blocking an enzyme called methionine aminopeptidase 2, which is crucial for cancer cells to grow and multiply.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Paveril TARGET | dioxyline | unknown | dioxyline | Methionine aminopeptidase 1, Methionine aminopeptidase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (dioxyline class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Paveril CI watch — RSS
- Paveril CI watch — Atom
- Paveril CI watch — JSON
- Paveril alone — RSS
- Whole dioxyline class — RSS
Cite this brief
Drug Landscape (2026). Paveril — Competitive Intelligence Brief. https://druglandscape.com/ci/dioxyline. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing